Literature DB >> 12481710

The role of membrane transporters in cellular resistance to anticancer nucleoside drugs.

Marilyn L Clarke1, John R Mackey, Stephen A Baldwin, James D Young, Carol E Cass.   

Abstract

Mesh：

Substances：

Year:  2002        PMID： 12481710     DOI： 10.1007/978-1-4615-1173-1_2

Source DB:  PubMed          Journal:  Cancer Treat Res        ISSN： 0927-3042


× No keyword cloud information.
  20 in total

1.  Imexon enhances gemcitabine cytotoxicity by inhibition of ribonucleotide reductase.

Authors:  Nicholas O Roman; Betty K Samulitis; Lee Wisner; Terry H Landowski; Robert T Dorr
Journal:  Cancer Chemother Pharmacol       Date:  2010-03-26       Impact factor: 3.333

Review 2.  Polymeric nanogel formulations of nucleoside analogs.

Authors:  Serguei V Vinogradov
Journal:  Expert Opin Drug Deliv       Date:  2007-01       Impact factor: 6.648

Review 3.  Uptake carriers and oncology drug safety.

Authors:  Jason A Sprowl; Alex Sparreboom
Journal:  Drug Metab Dispos       Date:  2013-12-30       Impact factor: 3.922

Review 4.  Pharmacogenetics and pharmacoepigenetics of gemcitabine.

Authors:  M Candelaria; E de la Cruz-Hernández; E Pérez-Cárdenas; C Trejo-Becerril; O Gutiérrez-Hernández; A Dueñas-González
Journal:  Med Oncol       Date:  2009-11-10       Impact factor: 3.064

5.  Stearoyl gemcitabine nanoparticles overcome resistance related to the over-expression of ribonucleotide reductase subunit M1.

Authors:  Woon-Gye Chung; Michael A Sandoval; Brian R Sloat; Dharmika S P Lansakara-P; Zhengrong Cui
Journal:  J Control Release       Date:  2011-08-07       Impact factor: 9.776

6.  FUN26 (function unknown now 26) protein from saccharomyces cerevisiae is a broad selectivity, high affinity, nucleoside and nucleobase transporter.

Authors:  Rebba C Boswell-Casteel; Jennifer M Johnson; Kelli D Duggan; Zygy Roe-Žurž; Hannah Schmitz; Carter Burleson; Franklin A Hays
Journal:  J Biol Chem       Date:  2014-07-17       Impact factor: 5.157

Review 7.  Genetic factors influencing cytarabine therapy.

Authors:  Jatinder K Lamba
Journal:  Pharmacogenomics       Date:  2009-10       Impact factor: 2.533

8.  Nucleoside transporter subtype expression and function in rat skeletal muscle microvascular endothelial cells.

Authors:  Richard G E Archer; Václav Pitelka; James R Hammond
Journal:  Br J Pharmacol       Date:  2004-08-02       Impact factor: 8.739

9.  Imatinib-resistant CML cells have low ENT activity but maintain sensitivity to gemcitabine.

Authors:  Andrea V Leisewitz; Eric I Zimmerman; Shannon Z Jones; Jing Yang; Lee M Graves
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2008-06       Impact factor: 1.381

10.  Bone marrow stromal cells modulate mouse ENT1 activity and protect leukemia cells from cytarabine induced apoptosis.

Authors:  Patricia Macanas-Pirard; Andrea Leisewitz; Richard Broekhuizen; Kelly Cautivo; Francisco M Barriga; Francisco Leisewitz; Victoria Gidi; Erick Riquelme; Viviana P Montecinos; Pilar Swett; Pelayo Besa; Pablo Ramirez; Mauricio Ocqueteau; Alexis M Kalergis; Matthew Holt; Michael Rettig; John F DiPersio; Bruno Nervi
Journal:  PLoS One       Date:  2012-05-22       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.